Nivolumab for the treatment of small cell lung cancer

Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Claudia Trojaniello, Maria Grazia Vitale, Vito Vanella, Marcello Curvietto, Paolo Antonio Ascierto

Research output: Contribution to journalArticle

Abstract

Introduction: Treatment of extensive-stage SCLC is still a challenge but immunotherapy with checkpoint inhibitors is showing promising results. Nivolumab alone or in combination with ipilimumab has demonstrated a benefit in terms of response and survival in patients with pre-treated extensive-stage disease and has been approved as third-line therapy after failure of chemotherapy. However, data from two phase III trials with nivolumab are negative. In the first trial, nivolumab was administered as a single agent compared to second-line chemotherapy, while in the second it was given alone or in combination with ipilimumab as maintenance treatment after platinum-based chemotherapy. Areas covered: Our review focuses on the role of immunotherapy, and in particular nivolumab, in the treatment of SCLC, describing the results of the main trials and its future perspectives, with reference to clinical trials with other checkpoint inhibitors. Expert opinion: The future of nivolumab in the treatment of SCLC needs to be clarified with further clinical trials, in which improved patient selection and a more specific setting and/or timepoint of the disease may be identified.

Original languageEnglish
JournalExpert Review of Respiratory Medicine
DOIs
Publication statusPublished - 2020

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Immunotherapy
Clinical Trials
Therapeutics
Expert Testimony
Platinum
Patient Selection
nivolumab
Survival
ipilimumab

Keywords

  • antiPD1 inhibitors
  • antiPDL1 inhibitors
  • chemotherapy
  • Nivolumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Nivolumab for the treatment of small cell lung cancer. / Simeone, Ester; Grimaldi, Antonio Maria; Festino, Lucia; Trojaniello, Claudia; Vitale, Maria Grazia; Vanella, Vito; Curvietto, Marcello; Ascierto, Paolo Antonio.

In: Expert Review of Respiratory Medicine, 2020.

Research output: Contribution to journalArticle

Simeone, Ester ; Grimaldi, Antonio Maria ; Festino, Lucia ; Trojaniello, Claudia ; Vitale, Maria Grazia ; Vanella, Vito ; Curvietto, Marcello ; Ascierto, Paolo Antonio. / Nivolumab for the treatment of small cell lung cancer. In: Expert Review of Respiratory Medicine. 2020.
@article{f1f00f3277184fe2b4272d34e9218ab5,
title = "Nivolumab for the treatment of small cell lung cancer",
abstract = "Introduction: Treatment of extensive-stage SCLC is still a challenge but immunotherapy with checkpoint inhibitors is showing promising results. Nivolumab alone or in combination with ipilimumab has demonstrated a benefit in terms of response and survival in patients with pre-treated extensive-stage disease and has been approved as third-line therapy after failure of chemotherapy. However, data from two phase III trials with nivolumab are negative. In the first trial, nivolumab was administered as a single agent compared to second-line chemotherapy, while in the second it was given alone or in combination with ipilimumab as maintenance treatment after platinum-based chemotherapy. Areas covered: Our review focuses on the role of immunotherapy, and in particular nivolumab, in the treatment of SCLC, describing the results of the main trials and its future perspectives, with reference to clinical trials with other checkpoint inhibitors. Expert opinion: The future of nivolumab in the treatment of SCLC needs to be clarified with further clinical trials, in which improved patient selection and a more specific setting and/or timepoint of the disease may be identified.",
keywords = "antiPD1 inhibitors, antiPDL1 inhibitors, chemotherapy, Nivolumab",
author = "Ester Simeone and Grimaldi, {Antonio Maria} and Lucia Festino and Claudia Trojaniello and Vitale, {Maria Grazia} and Vito Vanella and Marcello Curvietto and Ascierto, {Paolo Antonio}",
year = "2020",
doi = "10.1080/17476348.2020.1681977",
language = "English",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Nivolumab for the treatment of small cell lung cancer

AU - Simeone, Ester

AU - Grimaldi, Antonio Maria

AU - Festino, Lucia

AU - Trojaniello, Claudia

AU - Vitale, Maria Grazia

AU - Vanella, Vito

AU - Curvietto, Marcello

AU - Ascierto, Paolo Antonio

PY - 2020

Y1 - 2020

N2 - Introduction: Treatment of extensive-stage SCLC is still a challenge but immunotherapy with checkpoint inhibitors is showing promising results. Nivolumab alone or in combination with ipilimumab has demonstrated a benefit in terms of response and survival in patients with pre-treated extensive-stage disease and has been approved as third-line therapy after failure of chemotherapy. However, data from two phase III trials with nivolumab are negative. In the first trial, nivolumab was administered as a single agent compared to second-line chemotherapy, while in the second it was given alone or in combination with ipilimumab as maintenance treatment after platinum-based chemotherapy. Areas covered: Our review focuses on the role of immunotherapy, and in particular nivolumab, in the treatment of SCLC, describing the results of the main trials and its future perspectives, with reference to clinical trials with other checkpoint inhibitors. Expert opinion: The future of nivolumab in the treatment of SCLC needs to be clarified with further clinical trials, in which improved patient selection and a more specific setting and/or timepoint of the disease may be identified.

AB - Introduction: Treatment of extensive-stage SCLC is still a challenge but immunotherapy with checkpoint inhibitors is showing promising results. Nivolumab alone or in combination with ipilimumab has demonstrated a benefit in terms of response and survival in patients with pre-treated extensive-stage disease and has been approved as third-line therapy after failure of chemotherapy. However, data from two phase III trials with nivolumab are negative. In the first trial, nivolumab was administered as a single agent compared to second-line chemotherapy, while in the second it was given alone or in combination with ipilimumab as maintenance treatment after platinum-based chemotherapy. Areas covered: Our review focuses on the role of immunotherapy, and in particular nivolumab, in the treatment of SCLC, describing the results of the main trials and its future perspectives, with reference to clinical trials with other checkpoint inhibitors. Expert opinion: The future of nivolumab in the treatment of SCLC needs to be clarified with further clinical trials, in which improved patient selection and a more specific setting and/or timepoint of the disease may be identified.

KW - antiPD1 inhibitors

KW - antiPDL1 inhibitors

KW - chemotherapy

KW - Nivolumab

UR - http://www.scopus.com/inward/record.url?scp=85074811219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074811219&partnerID=8YFLogxK

U2 - 10.1080/17476348.2020.1681977

DO - 10.1080/17476348.2020.1681977

M3 - Article

C2 - 31622114

AN - SCOPUS:85074811219

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

ER -